Drug intelligence / Profile preview

MHB118C

Development stage: Phase 1
Lead developer: Minghui Pharmaceutical
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

MHB118C is an **antibody-drug conjugate (ADC)** under clinical investigation for the treatment of advanced solid tumors. It is being developed by Minghui Pharmaceutical. This agent is designed to improve antitumor activity by targeting cancer-associated antigens, enabling intracellular delivery of a cytotoxic payload to malignant cells. MHB118C is administered intravenously and is currently in early-stage clinical trials focused on establishing safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with advanced cancers[5][7][8][9][10].

Brand names: MHB118CMHB-118CMHB 118C
Other names: MHB118CMHB-118CMHB 118C

Beyond the preview

Go deeper on MHB118C.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MHB118C.

Explore the full profile